Synvista Therapeutics, Inc.
Not enough financial coverage to compute a composite score for SYNI. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Company
Synvista Therapeutics, Inc. , a product-based biopharmaceutical company, develops diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease. The company's products include ALT-2074, a glutathione peroxidase mimetic in Phase II clinical trials for the treatment of diabetic patients with Hp2-2; and Alagebrium chloride or alagebrium, an Advanced Glycation End-product Crosslink Breaker in Phase II clinical trials for the treatment of diastolic heart failure and diabetic nephropathy.
- IPO
- 2000
- Employees
- 9
- HQ
- Parsippany, US
Price Chart
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -5.15
- Avg Volume
- 260
Get TickerSpark's AI analysis on SYNI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SYNI Coverage
We haven't published any research on SYNI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SYNI Report →